Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis.

Breast · 2021 · PMC8377481 · PMID 34407499

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In this analysis metronomic CM showed a trend toward benefit observed in high-risk patient population with node-positive and triple negative subtype (N = 340) with an estimated 5-year DFS of 72.5 % for the CM maintenance group and was 64.6 % for the no-CM group (HR, 0.72; 95 % CI: 0.49 to 1.05) [ 9 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.